본문으로 건너뛰기
← 뒤로

[Brexu-cel cell therapy and subsequent allogeneic hematopoietic stem cell transplantation in the treatment of late-relapse B-cell acute lymphoblastic leukemia].

1/5 보강
Recenti progressi in medicina 2026 Vol.117(1) p. e5-e7 OA
Retraction 확인
출처

Brunello L

📝 환자 설명용 한 줄

Here we report the case of a 39 years old patient who experienced a hematological relapse of B-cell acute lymphoblastic leukemia 23 months after completion of maintenance therapy.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Brunello L (2026). [Brexu-cel cell therapy and subsequent allogeneic hematopoietic stem cell transplantation in the treatment of late-relapse B-cell acute lymphoblastic leukemia].. Recenti progressi in medicina, 117(1), e5-e7. https://doi.org/10.1701/4631.46412
MLA Brunello L. "[Brexu-cel cell therapy and subsequent allogeneic hematopoietic stem cell transplantation in the treatment of late-relapse B-cell acute lymphoblastic leukemia].." Recenti progressi in medicina, vol. 117, no. 1, 2026, pp. e5-e7.
PMID 41568643 ↗
DOI 10.1701/4631.46412

Abstract

Here we report the case of a 39 years old patient who experienced a hematological relapse of B-cell acute lymphoblastic leukemia 23 months after completion of maintenance therapy. Relapse occurred two days after brexu-cel approval for reimbursement within the Italian National Health System. This favourable timing enabled the prompt apheresis for brexu-cel manufacturing, bridge therapy with inotuzumab ozogamicin and subsequently brexu-cel infusion. The patient achieved a complete molecular remission and thereafter performed an allogeneic stem cell transplantation. Currently, at 19 and 15 months after brexu-cel infusion and transplant, respectively, the patient presents sustained MRD negative remission with no graft-versus-host-disease evidence and a good quality of life.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기